Ono Pharmaceutical Co Ltd
4528
Company Profile
Business description
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
Contact
1-8-2 Kyutarocho
Chuo-ku
Osaka541-8564
JPNT: +81 662635670
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2026
Employees
4,287
Stocks News & Analysis
stocks
Undervalued ASX share with pathway to positive cash flow
Higher sales and a new loan facility increase our conviction.
stocks
Taiwan Semiconductor earnings: Buoyant guidance backed by voracious AI demand
We’ve raised our fair value estimate of Taiwan Semiconductor stock.
stocks
Ahead of earnings, is Netflix a buy, a sell, or fairly valued?
Watching sales growth and the potential for a major acquisition, here’s what we think of Netflix stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,222.40 | 41.60 | 0.45% |
| CAC 40 | 8,313.12 | 17.84 | -0.21% |
| DAX 40 | 25,352.39 | 66.15 | 0.26% |
| Dow JONES (US) | 49,442.44 | 292.81 | 0.60% |
| FTSE 100 | 10,238.94 | 54.59 | 0.54% |
| HKSE | 26,851.69 | 71.93 | -0.27% |
| NASDAQ | 23,530.02 | 58.27 | 0.25% |
| Nikkei 225 | 54,106.32 | 4.18 | -0.01% |
| NZX 50 Index | 13,718.10 | 58.31 | 0.43% |
| S&P 500 | 6,944.47 | 17.87 | 0.26% |
| S&P/ASX 200 | 8,899.10 | 43.30 | 0.49% |
| SSE Composite Index | 4,103.45 | 9.16 | -0.22% |